CGON — CG Oncology Inc. stock price and chart

Share this page

CGON

$59.85-3.25%

as of close, Oct 16, 2026

☾ AH $59.85 -3.25%

CG Oncology Inc.Stock · HealthcareRussell 2000 0.2%Nasdaq Composite 0.01%US Stock Market 0.007%Russell 3000 0.007%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Jan 26, 2024

VolumeEEEE

202420252026

20.030.040.050.060.070.080.005.0M10.0M$59.85

2026-10-16

Price$59.85

MA20$70.58

MA50$69.50

Vol1.1M

What would $1,000 invested in CGON be worth today? →

CGON returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $59.85
YTD price return: +44.15%
YTD total return: +44.15%
Next earnings: Nov 13, 2026
Market cap: 5.3B2024-03 229.3M2026-10 5.3B+2214.6% over the window
Enterprise value: 4.3B
Shares outstanding: 88.6M2023-12 5.2M2026-06 88.6M+1597.3% over the window
52W low: $35.80
52W high: $80.97
From 52W high: -26.08%
From 52W low: +67.18%
52W range: 53%

Volume

Rel volume: 1.08×
30D volume: 999.5K
30D $ vol: 69.4M

Fundamentals

Sales (ttm): 6.2M2023-12 204K2026-06 6.2M+2952.9% over the window
Sales/share: $0.072023-12 $0.042026-06 $0.07+79.9% over the window
EPS (ttm): -$2.722023-12 -$15.652026-06 -$2.72-82.6% over the window
FCF (ttm): -179.3M2024-12 -78.9M2026-06 -179.3M+127.2% over the window
FCF/share: -$2.022024-12 -$1.042026-06 -$2.02+95.3% over the window
Book value/share: $11.612023-12 -$23.572026-06 $11.61-149.3% over the window
Net margin: -3602.68%2023-12 -23827.0%2026-06 -3602.7%-84.9% over the window
ROE: -21.80%2024-12 -12.0%2026-06 -21.8%+81.6% over the window
ROA: -20.67%2023-12 -24.4%2026-06 -20.7%-15.3% over the window
Debt / equity: 0.00×2024-12 0.002026-06 0.00
Current ratio: 22.222023-12 13.622026-06 22.22+63.2% over the window

Growth (CAGR, ttm) · 10Y

Sales: +1032.19%2025-06-30 → 2026-06-30551K → 6.2M (+1030.3% total)+293.21%2023-12-31 → 2026-06-30204K → 6.2M (+2952.9% total)n/an/a
Shares: +16.27%2025-06-30 → 2026-06-3076.2M → 88.6M (+16.3% total)+210.82%2023-12-31 → 2026-06-305.2M → 88.6M (+1597.3% total)n/an/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +873.80%2025-06-30 → 2026-06-30$0.01 → $0.07 (+872.3% total)+26.50%2023-12-31 → 2026-06-30$0.04 → $0.07 (+79.9% total)n/an/a
Book value/share: +32.08%2025-06-30 → 2026-06-30$8.79 → $11.61 (+32.1% total)n/an/an/a
Price: +43.05%2025-10-16 → 2026-10-16$41.85 → $59.85 (+43.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+19.11%2024-01-25 → 2026-10-16$37.17 → $59.85 (+61.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/an/a
Total return: +43.05%2025-10-16 → 2026-10-16$41.85 → $59.85 (+43.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+19.11%2024-01-25 → 2026-10-16$37.17 → $59.85 (+61.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/an/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -22.0×2024-03 -4.722026-10 -23.65+401.4% over the window
Fwd P/E: -21.1×
P/S (ttm)Market cap ÷ TTM revenue.: 851.8×2024-03 1123.812026-10 852.03-24.2% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 5.2×2024-03 -1.862026-10 5.16-376.9% over the window
EV/Sales (ttm): 688.1×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -3.38%2024-12 -3.6%2026-06 -2.8%-21.2% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 88.6M ÷ 76.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -16.27%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-16.27%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($2B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -16.27%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-539M) ÷ today's market cap ($5.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: -10.16%2023-12 0.0%2026-06 -8.6%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-539M + TTM dividends $0) ÷ today's market cap ($5.3B). Same caveat as the cash buyback yield.: -10.16%2023-12 0.0%2026-06 -8.6%

Performance · price return · as of 2026-10-16#

-3.25%

-6.22%

-19.25%

-13.88%

YTD

+44.15%

+43.01%

—

Financial statements

Open full CGON financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

CGON — CG Oncology Inc. price, chart and key statistics